FDA approves first autologous cellularized scaffold for the repair of cartilage defects of the knee

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA approves first autologous cellularized scaffold for the repair of cartilage defects of the knee

View as a webpage

News Release

For Immediate Release:

Dec. 13, 2016

Media Inquiries:

Andrea Fischer, andrea.fischer@xxxxxxxxxxx, 301-796-0393

Consumer Inquiries:

888-INFO-FDA

FDA approves first autologous cellularized scaffold for the repair of cartilage defects of the knee

The U.S. Food and Drug Administration today approved Maci (autologous cultured chondrocytes on porcine collagen membrane) for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients. Maci is the first FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient�s own knee.

Read more.

###

---

Subscriber Services:
Manage Preferences��|��Unsubscribe��|��Help with this service

Stay Connected:

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) � 10903 New Hampshire Ave � Silver Spring, MD 20993 � 1-888-INFO-FDA (1-888-463-6332)